One LAG-3 drug has reached the market, namely Bristol-Myers Squibb's Opdualag, which combines its PD-1 inhibitor Opdivo ...

CTLA-4 inhibitors are a well-established market in cancer care, and they are expected to grow significantly in the coming ...

BioNTech resumes its PRESERVE-003 trial for gotistobart as a monotherapy in metastatic squamous NSCLC after a partial ...

Cibisatamab is a monoclonal antibody commercialized by Roche, with a leading Phase II program in Squamous Non-Small Cell Lung Cancer.

Rilvegostomig is a monoclonal antibody commercialized by AstraZeneca, with a leading Phase III program in Non-Small Cell Lung Cancer.

A multi-institutional clinical trial led by the University of Navarra, Spain, found that blocking growth differentiation ...

BioNTech SE said on Friday it has been informed by its partner OncoC4 that the U.S. Food and Drug Administration has lifted ...

The study characterizes the lung cancer tumor microenvironment, linking cellular compositions to immunotherapy resistance and ...

The Institute for Clinical and Economic Review has identified five drugs — Biktarvy, Darzalex, Entresto, Cabometyx, and ...

Teos Therapeutics (ITOS) announced the presentation of clinical, translational, and preclinical data from its adenosine A2A receptor ...

The PD-L1 IHC 28-8 PharmDx test is used to provide information on PD-L1 expression as a biomarker for patient response to therapies containing anti-PD-1 antibodies.